3201-29-4

Usage

Physical form

white crystalline solid

Melting point

108-112°C

Solubility

soluble in organic solvents (e.g. ethanol, acetone, ethyl acetate), insoluble in water

Uses

production of pharmaceuticals and agrochemicals, synthesis of other organic compounds, chelating agent in metal ion extraction and purification processes.

Upstream product

• 302-15-8 methylhydrazine sulfuric acid 
• 141-97-9 ethyl acetoacetate 
• 105-45-3 acetoacetic acid methyl ester 
• 60-34-4 methylhydrazine 
• 108-26-9 3-methyl-2-pyrazoline-5-one 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 98553-54-9 3-(2-methyl-semicarbazono)-butyric acid ethyl ester 

Downstream Products

• 78431-21-7 5-chloro-1,3-dimethyl-4-phenyldiazenyl-1,2-diazacyclopenta-2,4-diene 
• 78431-23-9 methyl-azothiopyrine (1,3-dimethyl-5-mercapto-4-phenyldiazenyl-1,2-diazacyclopenta-2,4-diene) 
• 78431-25-1 1,3-dimethyl-5-methylthio-4-phenyldiazenyl-1,2-diazacyclopenta-2,4-diene 
• 37704-89-5 (1,3-dimethyl-5-hydroxy-1H-pyrazol-4-yl)phenylmethanone 
• 37704-91-9 2,5-dimethyl-4-(4-nitro-benzoyl)-1,2-dihydro-pyrazol-3-one 
• 62031-13-4 5-(4-chloro-benzoyloxy)-1,3-dimethyl-1H-pyrazole 
• 1177283-50-9 (5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methanamine 
• 96286-02-1 5-chloro-1,3-dimethyl-1H-pyrazole-4-carbonitrile 
• 27006-76-4 5-chloro-4-formyl-1,3-dimethylpyrazole 
• 85163-32-2 4-(2,4-dichloro-3-methylbenzoyl)-1,3-dimethyl-5-hydroxypyrazole 
• 58010-98-3 4-(2,4-dichlorobenzoyl)-1,3-dimethyl-5-hydroxypyrazole 
• 58011-01-1 1,3-dimethyl-4-(4-chlorobenzoyl)-5-hydroxypyrazole 
• 10250-58-5 1,3-dimethyl-5-phenyl-1H-pyrazole 
• 81649-68-5 1,2-dihydro-2,5-dimethyl-4-nitropyrazol-3-one 

Relevant academic research and scientific papers

Containing substituted 1, 3, 4-thiadiazole sulfide pyrazole amide and pyrazole imine derivatives and preparation method and application

The invention discloses pyrazole amide and pyrazole imine derivatives containing substituted 1, 3, 4-thiadiazole thioether as well as a preparation method and an application of the derivatives. The compounds have the structures as shown in formulae (I) and (II). The preparation method comprises the following steps: by taking substituted hydrazine as an initial raw material, carrying out closed loop, chlorine formylation, oxidation and chloro reaction to obtain pyrazole acyl chloride; carrying out a reaction on 2-amino-5-mercapto-1, 3, 4-thiadiazole and substituted benzyl chloride to obtain 2-amino-5-substituted 1, 3, 4-thiadiazole thioether; and then, carrying out a substitution reaction on 2-amino-5-substituted 1, 3, 4-thiadiazole thioether and substituted pyrazole acyl chloride to obtain the pyrazole amide compound (I) containing substituted 1, 3, 4-thiadiazole thioether; by taking substituted hydrazine as an initial raw material, carrying out closed loop and chlorine formylation to obtain pyrazole aldehyde; carrying out an additive elimination reaction on pyrazole aldehyde and 2-amino-5-mercapto-1, 3, 4-thiadiazole under a backflow condition of anhydrous ethanol to obtain 2-substituted pyrazole imidogen-5-mercapto-1, 3, 4-thiadiazole; and then carrying out a reaction on 2-substituted pyrazole imidogen-5-mercapto-1, 3, 4-thiadiazole and substituted benzyl chloride to generate the pyrazole imine compound (II) containing substituted 1, 3, 4-thiadiazole thioether. The compounds disclosed by the invention have a good inhibiting effect on tobacco mosaic virus and can be used for preparing anti-plant virus drugs.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS

The present invention relates to substituted benzene compounds and bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Cobalt doped ZnS nanoparticles as a recyclable catalyst for solvent-free synthesis of heterocyclic privileged medicinal scaffolds under infrared irradiation

This paper reports preparation and characterization of cobalt doped ZnS NPs and their catalytic application in the synthesis of heterocyclic privileged medicinal scaffolds involving pyrazolones (with excellent regioselectivity) and 1,3-oxathiolan-5-one frameworks under infrared irradiation. Nanoparticles have been prepared at room temperature by a wet chemical method. The heterogeneous catalysts were fully characterized by XRD, TEM, EDAX, ICP-AES and UV/Vis. Under infrared radiation (IR), the catalytic activity of Co doped ZnS NPs was about 40-fold higher under IR as compared to the conventional method. Nanocatalyst plays a dual role of catalyst as well as susceptor, and enhances the overall capacity to absorb IR in the reaction mixture. Doping by Co promotes the activity and selectivity of ZnS NPs as indicated by their high TOF value, providing the products with good to excellent yields. The surface acidity of NPs was measured by FTIR spectra of chemisorbed pyridine. The present method does not involve any hazardous organic solvent or catalyst. The introduction of nanocatalyst in an IR system offers promising features for the reaction response such as the shorter reaction time, simple work-up procedure, and purification of products by non-chromatographic methods. The catalyst was reused up to four runs without an appreciable loss of catalytic activity.

Mechanisms of Heterocycle Ring Formation. Part 5. A Carbon-13 Nuclear Magnetic Resonance Study of Pyrazolinone Synthesis by the Reaction of β-Ketoesters with Substituted Hydrazines

The 16 reactions between each of four hydrazines and four β-ketoesters have been followed by 13C n.m.r. spectroscopy.Peaks were assigned to starting materials, intermediates, and products, and reaction mechanisms determined and rationalized.Most rections proceed by attack of the least hindered hydrazine nitrogen atom on the keto carbon group of the ketoester.Relative rates of nucleophilic attack determine the build-up of intermediate and in some cases the nature of the products formed.

Compounds and compositions

Fungicidal compositions comprising as an active ingredient a compound of the general formula I STR1 wherein either R1 or R2 is the group STR2 in which X is an oxygen atom or a sulphur atom and R5 is straight chain alkyl group of 1 to 8 carbon atoms, branched chain alkyl group of 1 to 8 carbon atoms, cyclic alkyl group of 3 to 8 carbon atoms, alkenyl group, alkynyl group, hydroxyalkyl group phenyl group or a mono-, di- or tri- substituted phenyl group with substituents, which may be the same or different, chosen from the group consisting hydrogen alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, phenyl, halogen, trifluoromethyl, thiocyanate, nitro, cyano, amino, carboxy, alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl and N,N-dialkylcarbamoyl; when R1 is the group STR3 then R3 is hydrogen, alkyl, alkenyl alkynyl, hydroxyalkyl, phenyl, CH2 CF3 or the group --CH2 COOR6 wherein R6 is alkyl, phenyl or substituted phenyl, and R2 and R4, which may be the same or different, are hydrogen, alkyl, alkenyl, alkynyl, hydroxalkyl, alkoxy, phenyl, halogen, trifluoromethyl, thiocyanate, nitro, cyano, amino, carboxy, alkoxycarbonyl, carbamoyl, N,alkylcarbamoyl, N,N-dialkylcarbamoyl, hydroxy or mercapto provided that R2 and R4 are not both hydrogen, hydroxy or mercapto; when R2 is the group STR4 then R3 is hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkyl, phenyl or substituted phenyl, and R1 and R4, which may be the same or different, are hydrogen, alkyl, alkenyl, hydroxyalkyl, alkoxy, phenyl, substituted phenyl, halogen, trifluoromethyl, thiocyanate, nitro, cyano, amino, carboxy, alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, hydroxy or mercapto, provided that R1 and R3 are not both hydrogen and provided that R1 and R4 are not both hydroxy or mercapto; and an inert carrier material therefor.